探讨妊娠合并甲状腺功能亢进症对母婴影响及处理原则。

选取2006年1月至2010年12月于本院确诊并治疗分娩的52例妊娠合并甲状腺功能亢进症患者的病历资料为研究对象，按照治疗方式将其分为系统治疗组(n＝31)和非系统治疗组(n＝21)。采取回顾性分析方法，比较两组妊娠期并发症发生率、分娩方式及妊娠结局 (本研究遵循的程序符合本院人体试验委员会所制定的伦理学标准，得到该委员会批准)。两组患者年龄、孕次、产次、甲状腺功能亢进症分度及体重指数(body mass index, BMI)等比较，差异无显著意义(P>0.05)。

系统治疗组与非系统治疗组：①妊娠期并发症发生率比较[16.1%(5/31)vs. 95.2%(20/21)] ，差异有显著意义(P<0.01)；②人工助产率比较[67.7%(21/31)vs. 90.5%(19/21)] ，差异有显著意义(P<0.05)；③不良妊娠结局发生率比较[29.0 %(9/31) vs. 80.1%(17/21)]，差异有显著意义(P<0.05)。

积极、系统治疗妊娠合并甲状腺功能亢进症，对于防治妊娠期并发症及改善母婴预后具有重要意义。

To explore influence of pregnancy with hyperthyroidism on both maternal and infant and its treatment principle.

From January 2006 to December 2010, clinical data of 52 pregnant women who were diagnosed as hyperthyroidism in First People's Hospital of Foshan were included into this study, and divided into system treatment group(n=31)and non-system treatment group (n=21). The incidence rate of complications, delivery methods and the pregnancy outcomes were compared between two groups. The study protocol was approved by the Ethical Review Board of Investigation in Human Being of First People's Hospital of Foshan. There had no significant difference between two groups among age, gravidity, parity, degree of hyperthyroidism, hyperfunction sickness indexing and body mass index (BMI) (P>0.05), respectively.

①There had significant difference between system treatment group and non-system treatment group in incidence of complications during pregnancy[16.1%(5/31)vs. 95.2%(20/21); P<0.01]. ②Artificial aiding birth rates in system treatment group were obviously lower than those in non-system treatment group [67.7% (21/31)vs. 90.5% (19/21); P<0.05]. ③It also had significantly difference between system treatment group and non-system treatment group on incidence of adverse pregnancy outcomes [29.0% (9/31)vs. 80.1% (17/21); P<0.05) ].

Positive and systematic treatment for pregnant women with hyperthyroidism has great significance on decreasing incidence of complications and improving prognosis both in maternal and infant.